Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-quioxalin‑6‑ylmethylene‑thiazolidine‑2,4‑dione is a synthetic small molecule belonging to the quinoxaline and thiazolidinedione chemical classes. It acts as a potent and selective inhibitor of phosphatidylinositol 3‑kinase gamma (PI3Kγ), with an IC50 of approximately 8 nM. Preclinical studies have demonstrated its anti-inflammatory and antirheumatic properties by inhibiting the progression of joint inflammation and damage in both lymphocyte-independent and -dependent mouse models of rheumatoid arthritis. The compound has been explored primarily as an experimental tool compound for research into inflammatory diseases but has not advanced to clinical development or approval[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-quinoxalin-6-ylmethylene-thiazolidine-2,4-dione.